Table 1: Dosing information and baseline patient characteristics.

Description and dosing group allocation of 15 canine patients enrolled in the study. Patient breed, age, weight, tumor location, initial volume, and World Health Organization (WHO) domestic animal tumor stage are reported.

	Cohort 1x	Cohort 2x	Cohort 3.3x	Cohort 5x	Total
	(n=3)	(n=6)	(n=4)	(n=2)	(n=15)
Dosing Information
LAIR-CSA-IL-2 dose (“IL-2”; μg/kg)	17.4	34.8	57.4	87.0	80 doses
IL-12-CSA-LAIR dose (“IL-12”; μg/kg)	2.08	4.16	6.86	10.4	80 doses
Breed
Purebred
Miniature Schnauzer	1 (33%)	-	-	-	1 (6.7%)
German Shepard	1 (33%)	-	-	-	1 (6.7%)
German Shorthaired Pointer	-	1 (16.6%)	-	-	1 (6.7%)
Labrador Retriever	-	1 (16.6%)	1 (25%)	1 (50%)	3 (20%)
Dachshund	-	-	1 (25%)	-	1 (6.7%)
Yorkshire Terrier	-	-	1 (25%)	-	1 (6.7%)
Shih Tzu	-	1 (16.6%)	-	-	1 (6.7%)
Standard Poodle	-	-	-	1 (50%)	1 (6.7%)
Australian Cattle Dog	-	-	1 (25%)	-	1 (6.7%)
Mixed Breed	1 (33%)	3 (50%)	-	-	4 (26.7%)
Primary site of malignant melanoma [n (%)]
Lip/Buccal Mucosa	-	2 (33%)	-	1 (50%)	3 (20%)
Mandible/Mandibular Mucosa	1 (33%)	3 (50%)	1 (25%)	-	5 (33.3%)
Maxilla/Maxillary Mucosa	1 (33%)	1 (17%)	3 (75%)	1 (50%)	6 (40%)
Periocular	1 (33%)	-	-	-	1 (16.7%)
Age (years)
Median (min, max)	11 (4, 13)	11.5 (8, 16)	10.5 (7, 12)	10.5 (10, 11)	11 (4, 16)
Baseline weight (kg)
Median (min, max)	23.2 (5.8, 33.2)	16.5 (6.8, 33.9)	12.8 (4.7, 31.8)	34.9 (29.3, 40.4)	21.2 (4.7, 40.4)
Baseline tumor volume (cm3)
Median (min, max)	7.5 (4.7, 11.6)	6.8 (0.5, 16.3)	7.9 (2.7, 18.6)	23.2 (3.0, 43.4)	7.5 (0.5, 43.4)
Baseline WHO Stage [n (%)]
I	-	1 (17%)	-	-	1 (6.7%)
II	1 (33%)	2 (33%)	1 (25%)	-	4 (26.7%)
III	1 (33%)	2 (33%)	2 (50%)	-	5 (33%)
IV	1 (33%)	1 (17%)	1 (25%)	2 (100%)	5 (33%)